The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Acalabrutinib receives CHMP positive opinion for the treatment of patients with chronic lymphocytic leukemia
On 23 July, 2020, acalabrutinib received a positive opinion by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), recommending the granting of marketing authorisation for the treatment of adult patients with chronic lymphocytic leukemia (CLL).1
Acalabrutinib, a next-generation selective inhibitor of Bruton’s tyrosine kinase (BTK), was approved in the US for the treatment of adult patients with CLL and for adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.2
The positive opinion was based on the results from two randomised, multicenter, open-label, phase III clinical trials:2
- The ELEVATE TN trial (NCT02475681), comparing acalabrutinib combined with obinutuzumab vs acalabrutinib alone vs standard chemo-immunotherapy treatment (chlorambucil plus obinutuzumab) in patients with treatment-naïve CLL. Results from this trial showed a decrease in the risk of disease progression or death by 90% and 80% in patients treated with acalabrutinib combined with obinutuzumab and patients treated with acalabrutinib alone, respectively, compared with standard chemo-immunotherapy treatment
- The ASCEND trial (NCT02970318), evaluating acalabrutinib vs investigator’s choice of either rituximab in combination with idelalisib, or rituximab in combination with bendamustine in patients with relapsed or refractory CLL. In this trial, 88% of patients in the acalabrutinib arm remained alive and free from disease progression after 12 months compared with 68% of patients in the investigator’s choice arm
The CHMP recommendation is for1,2
- acalabrutinib as monotherapy or in combination with obinutuzumab for the treatment of adult patients with previously untreated CLL
- acalabrutinib as monotherapy for the treatment of adult patients with CLL who have received at least one prior therapy
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content